US 2004/0002460 A1 · Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom

Abstract

The present invention relates to protein components of spherons that are useful for identifying compounds capable of preventing and/or ameliorating symptoms of Alzheimer's Disease and/or dementia associated with cerebral amyloidosis. The invention also relates to the compounds identified by the methods, and methods of treating and/or ameliorating symptoms of Alzheimer's Disease and/or dementia associated with cerebral amyloidosis. The invention also relates to methods of making an Alzheimer's Disease or dementia associated with cerebral amyloidosis animal model or test animal, the animal model produced therefrom, and to a method of using the animal model to screen for effective therapies.

Claims50

Dependent claims

A composition comprising:

at least one comopund that binds to, antagonizes, or competes with a spheron component peptide other than a spheron component responsible for forming amyloid plaque, the spheron component peptide being selected from one or more of the group consisting of:
a) GEAAGAVQELAR (SEQ ID NO. 1);
b) GLSAASPPLAETGAPR (SEQ ID NO. 2);
c) ARAEAQEAEDQQAR (SEQ ID NO. 3);
d) VLAQLLR (SEQ ID NO. 4);
e) ALAHLLEAERQER (SEQ ID NO. 5);
f) AADHDVGSELPPEGVLGALLR (SEQ ID NO. 6);
g) LETPAPQVPAR (SEQ ID NO. 7);
h) ILAGSADSEGVAAPR (SEQ ID NO. 8);
i) ARPVKEPRGLSAASPPLAETGAPRRF (SEQ ID NO. 9);
j) ARPVKEP (SEQ ID NO. 10);
k) GLSAASPPLAETGAPRRF (SEQ ID NO. 11);
l) AADHDVGSELPPEGVLGALLRVKRLETPAPQVPA (SEQ ID NO. 12);
m) AADHDVGSELPPEGVLGALLRV (SEQ ID NO. 13);
n) LETPAPQVPA (SEQ ID NO. 14);
o) RRSVPRGEAAG (SEQ ID NO. 15);
p) VLAQLLRVWGAPRNSD (SEQ ID NO. 16);
q) PALGLDDDPDAPAAQLAR (SEQ ID NO. 17);
r) LARALLRARLDPAALAA (SEQ ID NO. 18);
s) QLVPAPVPAAALRPRPPVYDD (SEQ ID NO. 19);
t) GPAGPDAEEAGDE (SEQ ID NO. 20);
u) TPDVDPELLRYLLGR (SEQ ID NO. 21);
v) LLRVKR (SEQ ID NO. 22);
and
w) VLGALLRVKRLE (SEQ ID NO. 23).

22 more elements

A composition for treating dementia or cognitive impairment, comprising a pharmaceutically effective amount of a compound that functions in a manner selected from the group consisting of:

a) impedes or prevents the release from a spheron of proSAAS or a peptide fragment, variant, derivative, homologue, or mimetic thereof;
b) binds to, inhibits, antagonizes or competes with proSAAS or a peptide fragment, variant, derivative, homologue, or mimetic thereof that is released from a spheron;
c) reduces or prevents the cytotoxic effects of proSAAS or a peptide fragment, variant, derivative, homologue, or mimetic thereof that is released from a spheron;
and
d) counteracts the effects of the release from a spheron component of proSAAS or peptide fragment, variant, derivative, homologue, or mimetic thereof.

2 more elements

A method of identifying compounds useful in treating or ameliorating a neurological condition comprising:

transforming, transfecting or infecting cells, the transformed, transfected or infected cells comprising:
(a) a spheron component peptide other than a spheron component responsible for forming amyloid plaque;
(b) a polynucleotide encoding for a spheron component peptide other than a spheron component responsible for forming amyloid plaque;
or
(c) a polynucleotide that hybridizes under stringent conditions to (b);
administering a test compound to the transformed, transfected or infected cells;
and
identifying the compounds that ameliorate the effects of the spheron component other than a spheron component responsible for forming amyloid plaque.

5 more elements

A method of treating or ameliorating a neurological condition comprising:

administering to an animal in need thereof, a compound that functions in a manner selected from the group consisting of:
a) impedes or prevents the release from a spheron of proSAAS or a peptide fragment, variant, derivative, homologue, or mimetic thereof;
b) binds to, inhibits, antagonizes or competes with proSAAS or a peptide fragment, variant, derivative, homologue, or mimetic thereof that is released from a spheron;
c) reduces or prevents the cytotoxic effects of proSAAS or a peptide fragment, variant, derivative, homologue, or mimetic thereof that is released from a spheron;
and
d) counteracts the effects of the release from a spheron component of proSAAS or peptide fragment, variant, derivative, homologue, or mimetic thereof.

3 more elements

Dependencies are inferred from the claim text.

Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom

Life of this patent

Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom

Life of this patent

Abstract

Claims50